The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Enhanced treatment options, precision medicine, and advanced diagnostics are fueling growth across major markets Zollinger ...

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has received an average rating of “Hold” from the twenty-two brokerages that are presently covering the firm, MarketBeat reports. Two ...

If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved label updates for ...